TG Therapeutics, Inc. · TGTX · FY2026 Q3 · Calendar Q4 2026

TG Therapeutics raises 2026 revenue outlook as BRIUMVI momentum continues

The quarter's higher revenue outlook and management's account of increasing BRIUMVI adoption support a positive near-term commercial trajectory. Whether growth extends will depend on payer economics, competition, and execution of planned formulation and pipeline programs.

Why did TGTX rise 5.9% after missing EPS estimates in FY2026 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNASDAQHealthcare $10.07B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.35 Consensus $0.36
EPS surprise -2.6% Reported versus consensus
Reported revenue $259.9M Consensus $245.5M
Revenue surprise +5.9% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +5.9% Event window
SPY move +2.4% Same window
Abnormal move +3.6% Stock minus SPY
Volume 3.0× Versus trailing sessions
Subsequent drift +3.8% Up to 20 sessions
TGTXSPY benchmark

Ask FN2 about TGTX FY2026 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Management raised full-year global revenue guidance to $1 billion and U.S. BRIUMVI guidance to $915–$920 million. The call also highlighted long-term BRIUMVI data and early results for subcutaneous BRIUMVI and azer-cel. Compared with the prior-quarter analysis, the guidance direction remains raised, with a higher current outlook.

Guidance delta

Raised: global full-year revenue guidance is now $1 billion, and U.S. BRIUMVI net revenue guidance is $915–$920 million. The prior-quarter analysis recorded global guidance of approximately $950 million and U.S. guidance of $890–$905 million.

Key takeaways

  • Management cited physician adoption, hospital growth and treatment-naïve starts as commercial drivers.
  • BRIUMVI long-term follow-up data and early subcutaneous results featured in the call.
  • Early azer-cel results in progressive MS were described as encouraging, but the program remains investigational.
  • The reported revenue result exceeded consensus while EPS was below consensus.

Management priorities

  • Pursue approval and launch of the single-dose IV initiation regimen, targeted around mid-2027.
  • Prepare for a subcutaneous BRIUMVI launch with an auto-injector, targeted for 2028.
  • Advance azer-cel and studies in myasthenia gravis and schizophrenia; continue conference data presentations.
  • Maintain disciplined capital allocation and return cash to shareholders.

Follow TGTX with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
TGTX REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $40M Q4 '23 actual $44M, beat Q1 '24 estimate $55M Q1 '24 actual $63M, beat Q2 '24 estimate $66M Q2 '24 actual $73M, beat Q3 '24 estimate $99M Q3 '24 actual $84M, miss Q2 '25 estimate $146M Q2 '25 actual $141M, miss Q3 '25 estimate $194M Q3 '25 actual $162M, miss Q4 '25 estimate $192M Q4 '25 actual $193M, beat Q1 '26 estimate $200M Q1 '26 actual $205M, beat Q2 '26 estimate $230M Q2 '26 actual $240M, beat Q3 '26 estimate $245M Q3 '26 actual $260M, beat Q4 '26 estimate $290M Q1 '27 estimate $294M Q2 '27 estimate $323M Q3 '27 estimate $336M
Show less

Analyst Consensus ?

ConsensusBuy13 ratings
Bullish1184.6%
Neutral17.7%
Bearish17.7%

Analyst 52W Price Targets

$63.34Current
$11.5Low
$41Average
$83High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Evercore ISI Group Outperform OutperformMaintainNov 10, 2026
HC Wainwright & Co. Buy BuyMaintainSep 1, 2026
JP Morgan Overweight OverweightMaintainAug 7, 2026
B. Riley Securities Buy BuyMaintainJul 27, 2026
B of A Securities Underperform UnderperformMaintainJul 7, 2026
Show 8 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $63.34. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
H.C. WainwrightEmily Bodnar$78$46.17 +23.1%Aug 4, 2026
JefferiesAnalyst unavailable$83$54.4 +31.0%Jun 22, 2026
H.C. WainwrightAnalyst unavailable$70$39.75 +10.5%May 6, 2026
Goldman SachsAnalyst unavailable$39$29.54 -38.4%Jan 15, 2026
H.C. WainwrightEmily Bodnar$60$36.7 -5.3%Oct 6, 2025
See 8 more

Track every rating change on TGTX the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma.…

Historical context

All TGTX earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the TGTX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-11-10T00:12:30.985967+00:00
  2. FN2 earnings calendar · 2026-11-12T01:23:14.140288+00:00
  3. Polygon adjusted daily market bars · 2026-11-12T01:40:42.573310+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-12T01:40:42.570688+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-12. For educational purposes only; not investment advice.